52-year-old woman with stereotactic biopsy-proven intermediate grade DCIS,               upgraded to high-grade invasive ducal carcinoma. A) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip (arrow). B) Ultrafast imaging, post-contrast subtraction with TTE of 5 seconds (arrow)

52-year-old woman with stereotactic biopsy-proven intermediate grade DCIS, upgraded to high-grade invasive ducal carcinoma. 

A) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip (arrow). B) Ultrafast imaging, post-contrast subtraction with TTE of 5 seconds (arrow)


February 9, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), ultrafast (UF) MRI provides beneficial information that can be used in surgical planning, including determining the need to perform sentinel lymph node biopsy. 

“Preoperative UF-MRI, time to enhancement, and lesion size on conventional dynamic contrast-enhanced (DCE) MRI and mammography show potential in predicting upgrade of ductal carcinoma in situ (DCIS) to invasive cancer at surgery,” wrote first author Rachel Miceli, MD, of NYU Langone Health

This AJR accepted manuscript identifiedconsecutive women with biopsy-proven pure DCIS lesions who underwent UF-MRI with DCE-MRI and had subsequent surgery between August 2019 and January 2021. To determine predictors of upgrade to invasive cancer, patient and lesion characteristics; biopsy method and pathology; as well as lesion features on mammography, ultrasound, DCE-MRI, and UF-MRI were assessed. 

Ultimately, at surgery, 38% of lesions diagnosed as DCIS at percutaneous biopsy were upgraded to invasive cancer. Time to enhancement on UF-MRI was associated with upgrade from DCIS to invasive cancer (p=.03) with an optimal threshold of 11 seconds (specificity, 50%; sensitivity, 76%). 

Reiterating that short time to enhancement can assist prediction of lesions diagnosed as DCIS at percutaneous biopsy that will be upgraded to invasive cancer at surgery, “further studies with larger cohorts will be helpful in assessing the contribution of UF-MRI for the prediction of upgrade in clinical practice,” Miceli et al. concluded

For more information: www.arrs.org 


Related Content

News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
Subscribe Now